SpikeIns statistics

To access cutting-edge analytics on consensus tools, life science contexts and associated fields, you will need to subscribe to our premium service.


Citations per year

Citations chart

Popular tool citations

chevron_left Normalization chevron_right
Popular tools chart

Tool usage distribution map

Tool usage distribution map

Associated diseases

Associated diseases

SpikeIns specifications


Unique identifier OMICS_23424
Name SpikeIns
Software type Application/Script
Interface Command line interface
Restrictions to use None
Operating system Unix/Linux, Mac OS, Windows
Programming languages R
Computer skills Advanced
Stability Stable
Maintained Yes



Add your version


  • person_outline John C. Marioni <>

Publication for SpikeIns

SpikeIns in publications

PMCID: 2702171
PMID: 19584914
DOI: 10.1371/journal.pone.0006178

[…] cy5) was present; and third, by the performance of the non-h. glaberrima sequences printed on the array., for the first technical test, agilent's microarrays contain a series of internal controls (spikeins) that allow monitoring the technical performance of the array, in terms of linearity, sensitivity and accuracy. the 536 internal controls behaved as expected, e.g., spikein e1a_r60_n9 […]

PMCID: 2579310
PMID: 18947404
DOI: 10.1186/1471-2105-9-452

[…] inference is the most difficult, gcrma-nn provides a better accuracy with no loss of precision (fig. )., since the results of affycomp suggest an improvement for the low intensity, hard to detect spikeins, we reasoned that inference performed with gcrma-nn would be more successful than inference with gcrma-r or gcrma-l. we therefore applied gcrma-nn, gcrma-r and gcrma-l to the u133 latin […]

To access a full list of publications, you will need to upgrade to our premium service.

SpikeIns institution(s)
Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK; Wellcome Trust and MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK; EMBL European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK; Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK
SpikeIns funding source(s)
Supported by Cancer Research UK (award no. A17197), the University of Cambridge and Hutchison Whampoa Limited; by core funding from EMBL; by an EMBL Interdisciplinary Postdoctoral fellowship, supported by H2020 Marie Skłodowska Curie Actions; by Cancer Research UK, Bloodwise, the National Institute of Diabetes and Digestive and Kidney Diseases, the Leukemia and Lymphoma Society, and core infrastructure grants from the Wellcome Trust and the Medical Research Council.

SpikeIns reviews

star_border star_border star_border star_border star_border
star star star star star

Be the first to review SpikeIns